Key Points
- Director Lawrence Steinman bought 133,333 shares at $0.75 each (≈$99,999.75), raising his stake to 199,691 shares — a 200.93% increase in ownership.
- Pasithea's shares are under pressure — down 21.1% and trading near $0.75 with a market cap of about $8.6M, a reported ($0.41) EPS, and a consensus Sell rating (Weiss Ratings reiterated "sell").
Pasithea Therapeutics Corp. (NASDAQ:KTTA - Get Free Report) Director Simon Dumesnil bought 33,333 shares of the firm's stock in a transaction on Friday, November 28th. The shares were purchased at an average price of $0.75 per share, for a total transaction of $24,999.75. Following the purchase, the director owned 35,833 shares in the company, valued at $26,874.75. This trade represents a 1,333.32% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
Pasithea Therapeutics Price Performance
KTTA opened at $1.16 on Tuesday. The company has a 50 day simple moving average of $0.75 and a two-hundred day simple moving average of $0.76. The firm has a market cap of $8.63 million, a P/E ratio of -0.23 and a beta of 0.20. Pasithea Therapeutics Corp. has a 1-year low of $0.28 and a 1-year high of $3.85.
Pasithea Therapeutics (NASDAQ:KTTA - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.41) EPS for the quarter.
Institutional Investors Weigh In On Pasithea Therapeutics
Several large investors have recently made changes to their positions in the company. Citadel Advisors LLC lifted its position in shares of Pasithea Therapeutics by 43.7% in the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company's stock worth $48,000 after buying an additional 20,483 shares in the last quarter. Two Sigma Investments LP purchased a new position in Pasithea Therapeutics during the 3rd quarter valued at approximately $26,000. Finally, AdvisorShares Investments LLC increased its stake in Pasithea Therapeutics by 33.1% in the 3rd quarter. AdvisorShares Investments LLC now owns 257,696 shares of the company's stock worth $186,000 after acquiring an additional 64,149 shares during the last quarter. 23.92% of the stock is owned by institutional investors.
Analyst Ratings Changes
Separately, Weiss Ratings restated a "sell (e)" rating on shares of Pasithea Therapeutics in a research report on Monday, November 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Pasithea Therapeutics presently has an average rating of "Sell".
Get Our Latest Stock Report on KTTA
Pasithea Therapeutics Company Profile
(
Get Free Report)
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
